The Effects of Transfusion of Red blood cells In the critically ill II
Completed
- Conditions
- Anemiablood deficiency1000208610002252
- Registration Number
- NL-OMON48722
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 86
Inclusion Criteria
Patients who will receive an erythrocyte transfusion in the ICU (to correct for anemia) and are not suspected of an active bleeding.
Exclusion Criteria
* Patients who have not given informed consent
* Patients who pose difficulties in securing blood products (e.g. rare blood groups)
* Patients who receive more than 1 unit of RBCs in 1 transfusion episode
* No arterial catheter in situ
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Change in the expression of PS on erythrocytes before and after RBC transfusion<br /><br>and the influence of an inflammatory state in the receiver.</p><br>
- Secondary Outcome Measures
Name Time Method <p>* Clearance rate of erythrocytes<br /><br>- expression of clearance markers, other than PS<br /><br>* markers of immune cell and endothelial cell activation and adhesion<br /><br>* complete blood count<br /><br>* Levels of fibrinogen, APTT, PTT and D-dimers in blood (to calculate DIC score)<br /><br>* markers of inflammatory host respons<br /><br>* Sublingual microcirculatory density and perfusion velocity, as visualized<br /><br>with SDF<br /><br>* Tissue oxygenation, as measured with NIRS<br /><br>* VO2 (oxygen uptake), DO2 (oxygen delivery), O2ER (oxygen extraction ratio)<br /><br>* Time on mechanical ventilation<br /><br>* Duration of ICU stay<br /><br>* Duration of hospital stay<br /><br>* 28 day mortality<br /><br>* DNA staining on residual red blood cell material,<br /><br>* Red blood cell deformability, activation status and cell-binding ability</p><br>